NasdaqCM:CLDXBiotechs
Celldex Therapeutics (CLDX): Valuation in Focus After Disappointing Barzolvolimab Trial Results and Pipeline Shift
Celldex Therapeutics (CLDX) just announced the results from its Phase 2 trial of barzolvolimab in eosinophilic esophagitis, and the news has sparked fresh debate among investors. The drug hit its primary biological target by substantially reducing mast cell counts in the esophagus, but this breakthrough on the cellular level did not translate to meaningful symptom improvement for patients. As a result, the company is stopping development of barzolvolimab for this indication. However, it is...